Business Standard

Serum Institute of India buys Dutch vaccine maker for $40.3 mn

The acquisition gives Serum a manufacturing base in Europe and greater access to European and U.S. markets

Reuters  |  Mumbai 

  • ALSO READ

    PMO to meet next week on CIL's 65% assured supply to power cos

    BSE Sensex edges up, still in consolidation mode

    Entwistle is new BBC director-general

    Don't think I will marry again: Heidi Klum

    Peaches of over 10-year research stolen as just another fruit

of India, the country's top vaccine maker, has bought polio vaccine maker Bilthoven Biologicals from the government of Netherlands for 32 million euros, a top executive said.

The acquisition gives Serum a manufacturing base in Europe and greater access to European and U.S. markets, the company said in a statement on Wednesday.

Serum plans to invest about 70 million to 80 million euros, inclusive of the acquisition amount, over the next three years to expand Bilthoven's manufacturing capacity and meet working capital requirements, Adar Poonawalla, executive director, Serum, told Reuters over the phone.

Based in Pune, Serum Institute is the world's fifth-largest vaccine maker by volume.

The company plans to fund the acquisition by a combination of cash and debt, he said.

 

Serum Institute of India buys Dutch vaccine maker for $40.3 mn

The acquisition gives Serum a manufacturing base in Europe and greater access to European and U.S. markets

Serum Institute of India, the country's top vaccine maker, has bought polio vaccine maker Bilthoven Biologicals from the government of Netherlands for 32 million euros, a top executive said.

of India, the country's top vaccine maker, has bought polio vaccine maker Bilthoven Biologicals from the government of Netherlands for 32 million euros, a top executive said.

The acquisition gives Serum a manufacturing base in Europe and greater access to European and U.S. markets, the company said in a statement on Wednesday.

Serum plans to invest about 70 million to 80 million euros, inclusive of the acquisition amount, over the next three years to expand Bilthoven's manufacturing capacity and meet working capital requirements, Adar Poonawalla, executive director, Serum, told Reuters over the phone.

Based in Pune, Serum Institute is the world's fifth-largest vaccine maker by volume.

The company plans to fund the acquisition by a combination of cash and debt, he said.

 

image

Latest News